Ποια είναι η τιμή για Gracell Biotechnologies Inc. (GRCL)

Η τιμή για Gracell Biotechnologies Inc. (GRCL) είναι $10.25

Ποια είναι η κεφαλαιοποίηση αγοράς για Gracell Biotechnologies Inc. (GRCL)

Η κεφαλαιοποίηση αγοράς για Gracell Biotechnologies Inc. (GRCL) είναι $137.83M

Gracell Biotechnologies Inc. (GRCL) Δείκτης P/S

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.

Έτος	P/S Ratio	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

P/S Ratio

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	P/S Ratio	Διαφορά P/S Ratio	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Moderna, Inc. MRNA.US	11.28	-	US
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH

Εταιρεία

P/S Ratio

Διαφορά P/S Ratio

Χώρα